Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-09-17

Clinical Trial Update: Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing Ara-C at 18 g/m2 vs 12 g/m2 for 3 cycles as consolidation in acute myeloid leukemia; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ara-C (cytarabine)

Snippet

Sponsor: All India Institute of Medical Sciences | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: UNKNOWN